Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era

Zur Kurzanzeige

dc.identifier.uri http://dx.doi.org/10.15488/3782
dc.identifier.uri https://www.repo.uni-hannover.de/handle/123456789/3816
dc.contributor.author Klose, Johannes
dc.contributor.author Klose, Michelle A.
dc.contributor.author Metz, Courtney
dc.contributor.author Lehner, Frank
dc.contributor.author Manns, Michael P.
dc.contributor.author Klempnauer, Jürgen
dc.contributor.author Hoppe, Nils
dc.contributor.author Schrem, Harald
dc.contributor.author Kaltenborn, Alexander
dc.date.accessioned 2018-10-10T08:42:36Z
dc.date.available 2018-10-10T08:42:36Z
dc.date.issued 2014
dc.identifier.citation Klose, J.; Klose, M.A.; Metz, C.; Lehner, F.; Manns, M.P. et al.: Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era. In: Langenbeck's Archives of Surgery 399 (2014), Nr. 8, S. 1021-1029. DOI: https://doi.org/10.1007/s00423-014-1214-6
dc.description.abstract Purpose: Survival after liver transplantation (LTX) has decreased in Germany since the implementation of Model for end-stage liver disease (MELD)-based liver allocation. Primary sclerosing cholangitis (PSC) is known for its otherwise excellent outcome after LTX. The influence of MELD-based liver allocation and subsequent allocation policy alterations on the outcome of LTX for PSC is analyzed.Methods: This is a retrospective observational study including 126 consecutive patients treated with LTX for PSC between January 1, 1999 and August 31, 2012. The PSC cohort was further compared to all other indications for LTX in the study period (n = 1420) with a mean follow-up of 7.9 years (SD 3.2). Multivariate risk-adjusted analyses were performed. Alterations of allocation policy have been taken into account systematically.Results: Transplant recipients suffering from PSC are significantly younger (p < 0.001), can be discharged earlier (p = 0.018), and have lower 3-month mortality than patients with other indications (p = 0.044). The observed time on the waiting list is significantly longer for patients with PSC (p < 0.001), and there is a trend toward lower match MELD points in the PSC cohort (p = 0.052). No improvement in means of short-term mortality could be shown in relation to alterations of allocation policy within the MELD era (p = 0.375). Survival rates of the pre-MELD era did not differ significantly from those of the MELD era (p = 0.097) in multivariate risk-adjusted analysis. Patients in the MELD era suffered pre-transplant significantly more frequently from dominant bile duct stenosis (p = 0.071, p = 0.059, p = 0.048, respectively; chi2).Conclusions: Progress is stagnating in LTX for PSC. Current liver allocation for PSC patients should be reconsidered. eng
dc.language.iso eng
dc.publisher Heidelberg : Springer Verlag
dc.relation.ispartofseries Langenbeck's Archives of Surgery 399 (2014), Nr. 8
dc.rights CC BY 3.0 Unported
dc.rights.uri https://creativecommons.org/licenses/by/3.0/
dc.subject Autoimmune liver disease eng
dc.subject Cholangiocarcinoma eng
dc.subject MELD-based allocation eng
dc.subject Multivariate analysis eng
dc.subject Outcome eng
dc.subject Survival eng
dc.subject adolescent eng
dc.subject adult eng
dc.subject age distribution eng
dc.subject Article eng
dc.subject child eng
dc.subject cholestasis eng
dc.subject controlled study eng
dc.subject female eng
dc.subject follow up eng
dc.subject Germany eng
dc.subject graft recipient eng
dc.subject health care policy eng
dc.subject hospital admission eng
dc.subject hospital discharge eng
dc.subject human eng
dc.subject liver transplantation eng
dc.subject male eng
dc.subject Model For End Stage Liver Disease Score eng
dc.subject mortality eng
dc.subject multivariate analysis eng
dc.subject observational study eng
dc.subject outcome assessment eng
dc.subject primary sclerosing cholangitis eng
dc.subject resource allocation eng
dc.subject retrospective study eng
dc.subject risk assessment eng
dc.subject survival rate eng
dc.subject treatment indication eng
dc.subject aged eng
dc.subject Cholangitis, Sclerosing eng
dc.subject end stage liver disease eng
dc.subject epidemiology eng
dc.subject length of stay eng
dc.subject middle aged eng
dc.subject operation duration eng
dc.subject postoperative complication eng
dc.subject preschool child eng
dc.subject statistics and numerical data eng
dc.subject treatment outcome eng
dc.subject Adolescent eng
dc.subject Adult eng
dc.subject Aged eng
dc.subject Child eng
dc.subject Child, Preschool eng
dc.subject Cholangitis, Sclerosing eng
dc.subject End Stage Liver Disease eng
dc.subject Female eng
dc.subject Germany eng
dc.subject Health Policy eng
dc.subject Humans eng
dc.subject Length of Stay eng
dc.subject Liver Transplantation eng
dc.subject Male eng
dc.subject Middle Aged eng
dc.subject Operative Time eng
dc.subject Postoperative Complications eng
dc.subject Retrospective Studies eng
dc.subject Risk Assessment eng
dc.subject Survival Rate eng
dc.subject Treatment Outcome eng
dc.subject Waiting Lists eng
dc.subject.ddc 610 | Medizin, Gesundheit ger
dc.title Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era
dc.type Article
dc.type Text
dc.relation.issn 14352443
dc.relation.doi https://doi.org/10.1007/s00423-014-1214-6
dc.bibliographicCitation.issue 8
dc.bibliographicCitation.volume 399
dc.bibliographicCitation.firstPage 1021
dc.bibliographicCitation.lastPage 1029
dc.description.version publishedVersion
tib.accessRights frei zug�nglich


Die Publikation erscheint in Sammlung(en):

Zur Kurzanzeige

 

Suche im Repositorium


Durchblättern

Mein Nutzer/innenkonto

Nutzungsstatistiken